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NT1721 extends survival in pancreatic
cancer
Claudia M. Kowolik1†, Min Lin1†, Jun Xie1, Larry E. Overman2 and David A. Horne1*
Abstract
Background: Pancreatic cancer is one of the most lethal malignancies due to frequent late diagnosis, aggressive
tumor growth and metastasis formation. Continuously raising incidence rates of pancreatic cancer and a lack of
significant improvement in survival rates over the past 30 years highlight the need for new therapeutic agents.
Thus, new therapeutic agents and strategies are urgently needed to improve the outcome for patients with
pancreatic cancer. Here, we evaluated the anti-tumor activity of a new natural product-based
epidithiodiketopiperazine, NT1721, against pancreatic cancer.
Methods: We characterized the anticancer efficacy of NT1721 in multiple pancreatic cancer cell lines in vitro and in
two orthotopic models. We also compared the effects of NT1721 to clinically used hedgehog inhibitors and the
standard-of-care drug, gemcitabine. The effect of NT1721 on hedgehog/GLI signaling was assessed by determining
the expression of GLI and GLI target genes both in vitro and in vivo.
Results: NT1721 displayed IC50 values in the submicromolar range in multiple pancreatic cancer cell lines, while
largely sparing normal pancreatic epithelial cells. NT1721 attenuated hedgehog/GLI signaling through
downregulation of GLI1/2 transcription factors and their downstream target genes, which reduced cell proliferation
and invasion in vitro and significantly decreased tumor growth and liver metastasis in two preclinical orthotopic
mouse models of pancreatic cancer. Importantly, treatment with NT1721 significantly improved survival times of
mice with pancreatic cancer compared to the standard-of-care drug, gemcitabine.
Conclusions: Favorable therapeutics properties, i.e. 10-fold lower IC50 values than clinically used hedgehog
inhibitors (vismodegib, erismodegib), a 90% reduction in liver metastasis and significantly better survival times
compared to the standard-of-care drug, gemcitabine, provide a rational for testing NT1721 in the clinic either as a
single agent or possibly in combination with gemcitabine or other therapeutic agents in PDAC patients
overexpressing GLI1/2. This could potentially result in promising new treatment options for patients suffering from
this devastating disease.
Keywords: Pancreatic cancer, Epidithiodiketopiperazine, ETP, NT1721, GLI, Hedgehog signaling, Metastasis,
Orthotopic model
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Background
Pancreatic cancer is one of the most lethal cancers and
the 4th leading cause of cancer-related deaths in the
United States. Incidence rates have been on the raise
over the past several years: According to the American
Cancer Society an estimated 56,770 new cases will be di-
agnosed and 45,750 will die from the disease in 2019 [1].
Due to the lack of early symptoms and detection
methods, most patients are diagnosed with pancreatic
ductal adenocarcinoma (PDAC) at an advanced stage
when the tumor has metastasized and is not resectable
[2]. Gemcitabine became the standard-of-care drug for
PDAC two decades ago, improving median survival
compared to treatment with 5-fluorouracil (5.6 vs. 4.4
months) [3]. In recent clinical trials combinations of
gemcitabine with other drugs resulted in relatively mod-
est improvements of the median survival times [4]. A
clinical trial with FOLFIRINOX vs. gemcitabine showed
significantly improved median survival rates (11.1 vs. 6.8
months) in metastatic PDAC, but this regimen is associ-
ated with much higher toxicity rates that can only be
tolerated by very few patients [5]. Despite these ad-
vances, overall prognosis and survival rates have not
substantially improved over the past three decades,
remaining at an overall 5-year survival rate of 1–5% for
patients with metastatic PDAC [1, 2]. Major causes for
treatment failure are aggressive growth, early metastasis,
the development of gemcitabine resistance and enrich-
ment for cancer stem cells (CSCs) that survive chemo-
therapy and promote tumor recurrence [2, 6, 7]. Hence,
there is an urgent need to develop new drugs that can
overcome the drug resistance and improve the outcome
for patients with pancreatic cancer.
The sonic hedgehog (HH) pathway is a major regulator of
cell proliferation, differentiation and polarity that is fre-
quently aberrantly activated in a variety of cancers [4, 8, 9].
Canonical HH signaling is initiated through binding of sonic
hedgehog (SHH) to its receptor PTCH1, which ultimately
results in the activation of the zinc finger transcription fac-
tors GLI1/2 and the expression of GLI target genes [8]. GLI-
dependent transcription can also occur in the absence of
SHH since GLI transcription factors can be positively regu-
lated by PI3K-AKT, KRAS or TGFβ1 [10–12]. GLI target
genes (e.g. GLI1, PTCH1, BCL2, BMI1, DNMT1, CCNE1,
ABCG2) are involved in a wide variety of cellular processes
such as HH pathway feedback, proliferation, apoptosis and
stem cell self-renewal [8, 13–16]. Aberrant activation of
HH/GLI signaling has been implicated in increased prolifer-
ation, CSC signaling, epithelial-to-mesenchymal transition
(EMT) and thus increased metastasis in several types of can-
cer including PDAC [16, 17]. Moreover, increased HH sig-
naling may also contribute to gemcitabine resistance in
PDAC. Gemcitabine-resistant PDAC cells display increased
expression levels of members of the HH pathway, CSC and
EMT markers compared to the gemcitabine-sensitive paren-
tal cells [7, 17]. Various studies have shown that blocking
HH signaling with a SMO inhibitor (cyclopamine) decreases
the IC50 values for gemcitabine, downregulates CSC markers
and inhibits invasion and metastases in PDAC cells [17, 18].
Thus, targeting the HH/GLI pathway has emerged as prom-
ising strategy for the treatment of pancreatic cancer.
Epidithiodiketopiperazines (ETPs) are a broad class of
fungal metabolites with potent antitumor activity in
multiple solid and non-solid tumors. Here, we show for
the first time that the biological activity of an ETP,
NT1721, is associated with attenuated HH/GLI signal-
ing. We demonstrate that NT1721 reduced the expres-
sion of GLI and GLI target genes in pancreatic cancer
cell lines and two orthotopic mouse models. NT1721-
mediated downregulation of genes associated with EMT
resulted in significantly decreased metastases in vivo.
Importantly, NT1721 also significantly increased survival
times in an orthotopic model of pancreatic cancer com-
pared to the control and gemcitabine-treated groups,
highlighting its potential as new agent for the treatment
of pancreatic cancer.
Material and methods
Reagents
NT1721 was synthesized as previously described [19].
Erismodegib and vismodegib were purchased from
ApexBio (Houston, TX, USA).
Cell culture
Panc1, Capan1, SU.86.86 and BxPC3 cells were ob-
tained from ATCC (Manassas, VA, USA), authenti-
cated by STR-profiling at the source and passaged for
less than 6 months after receipt or resuscitation. The
cells were cultured in DMEM (Panc1, Capan1) or
RPMI (SU.86.86 and BxPC3) supplemented with 10%
FBS (Atlas Biologicals, Fort Collins, CO, USA).
Luciferase-expressing (luc+) Panc1 and Capan1 cells
were generated as previously described [20]. Immor-
talized, non-tumorigenic human pancreatic duct epi-
thelial cells (HPDEC) were obtained from AddexBio
(San Diego, CA, USA). Normal primary human pan-
creatic epithelial cells were purchased from Cell Sys-
tems (Kirkland, WA, USA) and cultured in Complete
Serum-Free Medium with RocketFuel™ (Cell Systems).
Determination of IC50 values
The cell viability and IC50 values were determined as
previously described [20] using the MTS assay (CellTiter
96® AQueous One Solution, Promega, Madison, WI,
USA); briefly, 7500 cells/well were seeded in 96-well
plates, cultured overnight and then treated with various
concentrations of NT1721 for 48 h. Data from the MTS
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assay were expressed as percent of viable cells compared
to the vehicle control (0.3% DMSO).
Proliferation assay
Cells were stained with CSFE ((5(6)-Carboxyfluorescein
N-hydroxysuccinimidylester, CellTrace™, ThermoFisher,
Waltham, MA, USA) according to the manufacturer’s
instructions, seeded at a concentration of 100,000 cells/
well in 12-well plates and allowed to attach overnight.
The cells were treated with NT1721 or DMSO the next
day, harvested after 24, 48 or 72 h, stained with 0.2 μg/
ml DAPI and subjected to FACS analysis. Fluorescence
data were collected on a CyAN flow cytometer (Beck-
man Coulter, Brea, CA, USA) and analyzed with FlowJo
software (TreeStar, Ashland, OR, USA).
Cell cycle analysis
Cells were treated with NT1721 and harvested after 24 h,
stained with propidium iodide (PI) (ThermoFisher) as pre-
viously described and subjected to FACS analysis [20].
QPCR
Total RNA was isolated using the Direct-zol kit (Zymo
Research, Irvine, CA, USA) and reverse transcribed
using the Tetro cDNA synthesis kit (Bioline, Taunton,
MA, USA).
The following qPCR primers were used:
ACTB: 5’CCAACCGCGAGAAGATGA /
5’CCAGAGGCGTACAGGGATAG;
ABCG2: 5’TGGCTTAGACTCAAGCACAGC /
5’TCGTCCCTGCTTAGACATCC;
CCNE1: 5’GGCCAAAATCGACAGGAC / 5′
GGGTCTGCACAGACTGCAT;
CDK2: 5′ AAAGCCAGAAACAAGTTGACG /
5’GTACTGGGCACACCCTCAGT;
DNMT1: 5’CAAACCCCTTTCCAAACCTC /
5’TAATCCTGGGGCTAGGTGAA;
GAPDH: 5’AGCCACATCGCTCAGACAC /
5’GCCCAATACGACCAAATCC;
GLI1: 5’ACCCGGGGTCTCAAACTG /
5’GGCTGACAGTATAGGCAGAGC;
GLI2: 5’CACGCTCTCCATGATCTCTG /
5’CCCCTCTCCTTAAGGTGCTC;
PTCH1: 5’CATGTTTGCACCCGTCCT /
5’CCAGCACAGCAAGAAATACC;
ZEB1: 5’CCTAAAAGAGCACTTAAGAATTCACAG /
5’CATTTCTTACTGCTTATGTGTGAGC;
ZEB2: 5’AGGAGCTGTCTCGCCTTG /
5’GGCAAAAGCATCTGGAGTTC.
Quantitative PCR was performed using a CFX96
Touch Real-Time PCR detection system (Bio-Rad).
Relative expression levels were calculated using the
2−ΔΔCt method and GAPDH or ACTB as reference
gene.
Western blots
SDS-PAGE and Western blots were carried out as previ-
ously described [20]. Briefly, cells were lyzed using RIPA
buffer (Cell signaling, Danvers, MA, USA) supplemented
with Halt Protease inhibitor cocktail (ThermoFisher Sci-
entific). The protein concentration was quantified using
the Pierce BCA Protein Assay Kit (ThermoFisher Scien-
tific). Equal amounts of protein were loaded on precast
gels (Bio-Rad, Hercules, CA, USA), transferred to PVDF
membranes (Bio-Rad) using the Trans-Blot Turbo Trans-
fer System (Bio-Rad). Membranes were blocked for 1 h at
RT in blocking buffer (5% w/v nonfat dry milk, 0.1%
Tween-20 in TBS), incubated with primary antibodies
overnight at 4 °C. Primary antibodies were purchased from
Cell signaling (CDH2 (#13116), β-actin (#4970), BIM
(#2933), BMI1 (#69640, DNMT1 (#5031), GAPDH
(#5174), H3 (#4499), p21 (#2947), ABCG2 (#42078), BCL2
(#4223), CDK2 (#2546), MMP2 (#13132)), from Santa
Cruz Biotchnology (GLI2 (sc-271,786), GLI1 (sc-20,687),
ZEB2 (sc-271,984)), from Millipore (Burlington, MA,
USA) (PTCH1 (06–1102)), from ThermoFisher (myc tag
(# MA1–21316)) and from Genetex (Irvine, CA, USA)
(ZEB1 (GTX55847)). The membranes were washed three
times with TBS and then incubated 1 h at RT with the ap-
propriate secondary antibodies. Bands were visualized
using X-ray film or the ChemiDoc Imaging System (Bio-
Rad) and analyzed with ImageJ or with Image Lab Soft-
ware (Bio-Rad).
GLI reporter assay
To establish a GLI reporter cell line, Capan1 cells were
transduced with a lentiviral vector (pGreenFire1 tm-
GLI-EF1-Neo, SBI System Biosciences, Palo Alto, CA,
USA) that expresses firefly luciferase under the control
of four GLI response elements. Transduced cells were
selected with 600 μg/ml G418. Capan1 GLI reporter cells
were seeded in 96-well plates (12,000 cells/well), allowed
to attach over night and then treated with NT1721, eris-
modegib or vismodegib. The medium was removed after
36 h and D-luciferin (300 μg/ml) was added. The lumi-
nescence was measured after 5 min of incubation at
37 °C. The luminescence values were normalized to the
protein concentration (Pierce BCA Protein Assay Kit)
and then to the DMSO control.
Invasion assay
To quantify the invasion of PDAC cell lines through the
basement membrane we performed the CytoSelect™ 96-
Well Cell Invasion Assay (Cell Biolabs, San Diego, CA,
USA) according to the manufacturer’s instructions.
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GLI2 overexpression
Plasmid pCS2-MT GLI2 delta N (#17649) expressing
GLI2ΔN, which displays strong transcriptional activity
[21], was obtained from Addgene (Watertown, MA,
USA). Panc1 and Capan1 cells were transfected with
pCS2-MT GLI2 delta N or a GFP-expressing control
plasmid using jetPrime transfection reagent (Polyplus
New York, NY, USA) according to the manufacturer’s
instructions. The cells were trypsinized after 16 h, seeded
into multiple wells, allowed to attach (8 h) and treated
with NT1721 for 48 h.
In vivo studies
Mouse care and experimental procedures were per-
formed under pathogen-free conditions in accordance
with approved protocols from the institutional animal
care and use committee of City of Hope National Med-
ical Center. For the orthotopic model, 5 × 105 luciferase-
expressing Panc1 or Capan1 cells were injected into the
pancreas of 6-to 8-week old male NSG mice (Jackson
Laboratory, Bar Harbor, ME, USA). To determine the
tumor burden, we injected the mice (I.P.) with 3 mg D-
Luciferin (Promega) 12 days after tumor injection and
imaged them in an IVIS 100 (Caliper Life Sciences). A
standard region of interest (ROI), which included the en-
tire mouse, was used to determine the total body bio-
luminescence. Data were expressed as photons/s/mm2.
The mice were then distributed into groups bearing
equal tumor burdens and treated with NT1721 (30 mg/
kg on 3 consecutive days per week by gavage) or gemci-
tabine (100 mg/kg, twice per week on non-consecutive
days by I.P. injection). The control groups for NT1721
and gemcitabine received the vehicle control (5% DMSO
/ 30% solutol (Sigma, St. Louis, MO, USA)) and PBS,
respectively.
Microscopy
H&E (Hematoxylin & Eosin) stained tissue slides were
prepared from formalin-fixed mouse livers using stand-
ard methods. Pictures of these tissue slides were taken
using a Zeiss Observer Z1 Widefield Microscope with a
506 Axioam Color Camera (Tiling option in Zen Blue
software, 10% overlap) and analyzed with Image Pro
Premier software (Media Cybernetics) to determine the
number of tumor foci/μm2.
Statistical analysis
The mean ± standard deviation (SD) was calculated for
each treatment group. Unless noted otherwise, the 2-
tailed t-test with Welch’s correction was used to deter-
mine statistical significance between two treatment
groups. The log-rank test was used to evaluate the statis-
tical significance in survival curves. p values < 0.05 were
considered to be significant.
Results
NT1721 displayed IC50 values in the nanomolar range in
multiple PDAC cell lines
To evaluate the potency of NT1721 against PDAC we
treated four pancreatic cancer cell lines (derived from either
primary tumors (Panc1, BxPC3) or from liver metastases
(Capan-1, SU.86.86)) with NT1721 and determined their
viability and the IC50 values after 48 h. As shown in Fig. 1a,
the IC50 values were all < 1 μM, ranging from ~ 150 to 800
nM, depending on the cell line. To assess the effect of
NT1721 on normal cells we also treated normal primary as
well as immortalized, non-tumorigenic pancreatic duct epi-
thelial cells (HPDEC) with NT1721. As shown in Fig. 1b,
NT1721 decreased the viability of the PDAC cell lines while
≥75% of the normal primary and HPDEC cells remained vi-
able at a concentration of 1 μM NT1721, suggesting that
NT1721 may preferentially decrease the viability of pancre-
atic tumor cells. We used invasive Panc1 and Capan1 cells,
expressing mutated KRAS, which is prevalent in the major-
ity of PDAC patients, to investigate the effect of NT1721
on PDAC in vitro and in vivo.
NT1721 decreased proliferation and cell cycle progression
We investigated the effect of NT1721 on the prolifera-
tion rate by staining Panc1 and Capan1 cells with
CSFE and treating them with NT1721 for 24 to 72 h.
FACS analysis of live cells showed that relatively low
concentrations of NT1721 (30 nM) significantly de-
creased proliferation in both Panc1 and Capan1 cells
after 48 h by 19 and 48%, respectively (p = 0.0003 for
both). Treatment with 30 nM NT1721 for 24 h led
only in Capan1 cells to significantly reduced prolifera-
tion (p = 0.001), but not in Panc1 cells (Fig. 1c). We
then assessed the effect of NT1721 on the cell cycle by
staining NT1721-treated cells with PI after 24 h.
NT1721 significantly increased the percentage of cells
in G1 phase and decreased the S phase in Capan1 cells
compared to the control (Fig. 1d), which is in line with
the decreased proliferation we detected in this cell line
after 24 h. The result suggests that NT1721 decreased
cell cycle progression in Capan1 cells after 24 h. In
contrast, Panc1 cells did not display a significant
change in the cell cycle after 24 h, which is not sur-
prising given that we did not observe a change in pro-
liferation at this early time point (Fig. 1c,d).
NT1721 downregulated GLI transcription factors and their
downstream target genes
Since we have previously shown that NT1721 decreased
DNMT1 and BMI1 expression in AML cells [20] we first
confirmed on the protein level that NT1721 also downreg-
ulated these genes in PDAC cells (Fig. 2a). Given that both
genes are targets of GLI transcription factors [13, 22] we
investigated whether their downregulation might be (at
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least partially) mediated by decreased GLI signaling: RNA-
seq data from various cancer cell lines suggested that
treatment with NT1721 led to the downregulation of
GLI1 and GLI2, which we then confirmed on the mRNA
(Fig. 2b) and protein level (Fig. 2a) in Panc1 and Capan1
cells. A time-course experiment revealed that NT1721
(500 nM) significantly decreased GLI1 and GLI2 mRNA
levels after 8 h of treatment. However, GLI2 mRNA ex-
pression was significantly reduced earlier (after 4 h) and to
a much greater degree in both cell lines compared to
GLI1 expression (Fig. 2c), suggesting that GLI2 may be a
major (direct or indirect) target of NT1721. To confirm
that GLI signaling was aberrantly activated in Panc1 and
Capan1 cells we compared GLI mRNA expression levels
of PDAC and non-tumorigenic HPDEC cells: GLI1
mRNA levels were overexpressed in both PDAC cell lines
by 6–20-fold. GLI2 mRNA levels were only elevated in
Capan1 cells (Fig. 2d). These results confirmed the aber-
rant activation of the HH pathway in these cell lines since
high GLI1 mRNA expression levels are considered to be a
reliable indicator of activated HH signaling; high GLI2
levels are also a sign of activated HH signaling because
GLI2 induces GLI1 transcription by binding to its pro-
moter [23]. In contrast, upregulation of GLI2 by GLI1 is
presumed to be indirect [24]. Moreover, BMI1 was also
significantly overexpressed in both PDAC cell lines
Fig. 1 IC50 values of NT1721 and its effects on proliferation and cell cycle in PDAC cells. a Pancreatic cancer cell lines were treated with
increasing concentrations of NT1721. The cell viability and IC50 values were determined after 48 h. The IC50 values represent the mean ± SD from
three experiments. b Effect on normal pancreatic epithelial cells. PDAC cell lines, normal primary pancreatic epithelial cells and immortalized, non-
tumorigenic pancreatic duct epithelial cells (HPDEC) were treated with 0.3% DMSO or NT1721 and the cell viability was determined after 48 h
using untreated cells as control. c Proliferation inhibition. PDAC cells were stained with CSFE, treated with NT1721 and subjected to FACS analysis
to determine the mean fluorescence intensity after 24, 48 or 72 h. The data were normalized to the control. The values represent the mean ± SD
from three experiments. d Cell cycle analysis. The cells were treated with NT1721, stained with PI after 24 h and analyzed by FACS. The symbols
(1* - 6*) indicate statistically significant differences compared to the control with p values of 0.0005, 0.0015, 0.015, 0.0022, 0.0054 and 0.0388,
respectively. The values represent the mean ± SD from four experiments
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compared to HPDEC cells (Fig. 2d), which is in line with
reports showing that BMI1 expression depends on HH
pathway activity in several tumors [16, 25, 26]. To further
verify that GLI-mediated signaling was attenuated after
treatment with NT1721 we determined the expression
levels of additional downstream targets of the GLI
transcription factors: PTCH1, BCL2, CCNE1 and ABCG2
[9, 15, 26, 27]. QPCR analyses revealed that these genes
were also downregulated after treatment with NT1721 for
24 h (Fig. 2e). Downregulation of PTCH1, BCL2, CCNE1
and ABCG2 was also confirmed on the protein level (Fig.
2f). Taken together, these results suggest that NT1721
may decrease HH/GLI signaling through downregulation
of GLI transcription factors.
NT1721 displayed significantly lower IC50 values than
clinically used hedgehog pathway inhibitors
To compare the efficacy of NT1721 and clinically
used hedgehog inhibitors (i.e. erismodegib, vismode-
gib) against PDAC we treated Panc1 and Capan1 cells
with the drugs or NT1721. Treatment of Panc1 cells
for 48 h with 1 or 10 μM NT1721 reduced the viabil-
ity by 50 and 69%, respectively, while treatment with
10 μM erismodegib or vismodegib resulted only in a
7–12% reduction in viability (Fig. 3a). Our results are
in line with previous reports showing that vismodegib
did not significantly reduce Panc1 viability at low mi-
cromolar concentrations (1 μM) [28–30]. Similar ef-
fects were observed in Capan1 cells: Treatment of
Fig. 2 NT1721-mediated downregulation of GLI and GLI target genes. a PDAC cells were treated with NT1721 and protein expression levels were
assessed by Western blot after 36 h. b-e The qPCR data were analyzed using GAPDH as reference gene. The data represent the mean ± SD from 4
independent experiments. b GLI1 and GLI2 mRNA levels were determined in Panc1 and Capan1 cells after treatment with NT1721
for 24 h. c Comparison of GLI1, GLI2 and BMI1 mRNA levels in PDAC and non-tumorigenic HPDEC cells. d NT1721-mediated time-dependent
downregulation of GLI mRNA in Panc1 and Capan1 cells. The asterisks indicate statistically significant differences compared to the
respective controls: 1* p = 0.0055; 2* p = 0.0032; 3* p = 0.0045; 4* p < 0.0001; 5* p = 0.0083; 6* p = 0.0004. e mRNA downregulation of GLI target
genes (PTCH1, BCL2, CCNE1, ABCG2) in Panc1 and Capan1 cells after 24 h treatment with NT1721. f Western blots of GLI target
genes (PTCH1, BCL2, CCNE1, ABCG2)
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Capan1 cells with 1 or 10 μM NT1721 reduced the
viability by 69 and 82%, respectively, while treatment
with 10 μM erismodegib or vismodegib reduced the
viability only by 10–13%. These results indicate that
10-fold lower concentrations of NT1721 led to a sig-
nificantly better reduction in cell viability in both
Panc1 and Capan1 cells compared to erismodegib and
vismodegib. To assess the effect of the drugs on
hedgehog signaling we also compared their effect on
the expression of hedgehog/GLI target genes. Treating
PDAC cells with 10 μM erismodegib or vismodegib
did not significantly reduce the GLI1, PTCH1 and
BCL2 mRNA expression (Fig. 3b). In contrast, treat-
ment of PDAC cells with 500 nM NT1721 was suffi-
cient to significantly decrease the expression of GLI1,
PTCH1 and BCL2, demonstrating that NT1721 re-
duced the expression of hedgehog/GLI target genes at
20-fold lower concentrations compared to erismode-
gib and vismodegib. To further assess the effect of
the drugs on hedgehog/GLI signaling, we established
a Capan1 GLI reporter cell line using a lentiviral vec-
tor that expressed luciferase under the control of four
GLI response elements. We treated the Capan1 GLI
reporter cell line with the drugs and measured the lu-
ciferase activity after 36 h. Treatment with 1 μM
NT1721 was sufficient to significantly reduce the lu-
minescence while 10-fold higher concentrations of
erismodegib or vismodegib did not significantly affect
the luminescence (Fig. 3c). However, a significant re-
duction in luminescence was observed after treatment
with 25 μM erismodegib or vismodegib, indicating
that NT1721 decreased the luminescence and thus
hedgehog/GLI signaling at 25-fold lower concentra-
tions. Taken together, our data show that NT1721
Fig. 3 NT1721 reduced PDAC cell viability and hedgehog/GLI signaling significantly better than clinically used hedgehog inhibitors. a Viability of
Panc1 and Capan1 cells treated with NT1721, erismodegib or vismodegib. b PTCH1 and BCL2 mRNA expression in and Capan1 cells treated with
NT1721, erismodegib or vismodegib. c Capan1 GLI reporter cells were treated with NT1721, erismodegib or vismodegib. The bioluminescence
was measured after 48 h and normalized to the control. The graphs represent the mean ± SD from triplicate values
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reduced hedgehog/GLI signaling at significantly lower
concentrations in both Panc1 and Capan1 cells com-
pared to erismodegib and vismodegib.
NT1721 induced the expression of tumor suppressor
genes and decreased the invasive potential of PDAC
Decreased BMI1 expression has been linked to the re-
expression of several tumor suppressor genes including
BIM (BCL2L11), p21 (CDKN1A) [31, 32]. Thus we ex-
amined whether the NT1721-mediated reduction of
BMI1 expression induced the re-expression of these
tumor suppressors. As shown in Fig. 4a, NT1721 led to
a strong upregulation of BIM and p21 in both cell lines.
Treatment with NT1721 was also associated with a sig-
nificant, > 80% decrease in CDK2 mRNA levels in both
cell lines (Fig. 4b), which was confirmed on the protein
level (Fig. 4a). This is in line with previous reports show-
ing that lower BMI1 expression levels are associated
with decreased CDK2 expression and thus cell cycle pro-
gression and proliferation [32–34].
Since aberrant HH/GLI signaling is linked to increased
EMT, invasion and metastasis in various cancers including
PDAC [16, 17] we assessed the effect of NT1721-mediated
GLI downregulation on the invasive potential of PDAC
cells: We used the CytoSelect™ Cell Invasion Assay (Cell
Biolabs) to quantify the ability of NT1721-treated PDAC
Fig. 4 NT1721 induced tumor suppressor genes and decreased the invasive potential of pancreatic cancer cell lines. a NT1721-mediated
induction of tumor suppressor genes (BIM, p21) and CDK2 was assessed by Western blot after 24 h using GAPDH as loading control. b CDK2
mRNA expression was determined after 24 h treatment of Panc1 and Capan1 cells with NT1721; GAPDH was used as reference gene.
The graphs represent the mean ± SD from 4 independent experiments. c PDAC cell lines were treated with NT1721 for 16 h. Their invasive
potential was quantified using the CytoSelect™ 96-Well Cell Invasion Assay (Cell Biolabs). d qPCR to determine ZEB1 and ZEB2 mRNA expression
levels in PDAC cells and non-tumorigenic HPDEC cells. GAPDH was used as reference gene. The graphs represent the mean ± SD from 4
experiments. e Protein expression of EMT markers (ZEB1, ZEB2, CDH2, MMP2) was determined by Western blot in Panc1 and Capan1
cells after 48 h treatment with NT1721. f The mRNA expression of EMT markers (MMP2, CDH2) was assessed in Panc1 and Capan1
cells after 24 h treatment with NT1721
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cell lines to migrate through the basement membrane.
NT1721 significantly reduced the migration through the
basement membrane in a concentration-dependent manner
by 2–3-fold in all PDAC cell lines (Fig. 4c). To investigate
the changes leading to the decreased invasion we then ex-
amined the expression of several genes associated with
EMT and invasion: Previous reports show that HH/GLI sig-
naling can indirectly induce the EMT-associated expression
of ZEB1 and ZEB2 [27, 35]. Thus, we first verified that the
ZEB transcription factors were upregulated in the PDAC
cells by comparing the mRNA expression levels in Panc1,
Capan1 and non-tumorigenic HPDEC cells: Both ZEB1
and ZEB2 were highly expressed in Panc1 and Capan1 cells
compared to HPDEC (Fig. 4d), suggesting that GLI
signaling may (at least partially) drive their expression.
Treatment of PDAC cells with NT1721 reduced the mRNA
expression of both ZEB1 and ZEB2 in Panc1 and Capan1
cells (Fig. 4d) and downregulation of ZEB1 was also con-
firmed on the protein level (Fig. 4e). We then also investi-
gated whether NT1721 (similar to HH inhibitors such as
GANT61, erismodegib and cyclopamine) could decrease
the expression of CDH2 and MMP2 [36–38]. As shown in
Fig. 4f, NT1721 decreased the mRNA expression of both
CDH2 and MMP2 in Panc1 cells. Downregulation of
CDH2 was also confirmed on the protein level in Panc1
cells (Fig. 4e). No CDH2 mRNA or protein expression was
detected in Capan1 cells (Fig. 4e,f). Taken together, the data
suggest that NT1721 reduced the invasive potential of
PDAC cells through downregulation of multiple EMT
markers.
Antitumor effects of NT1721 depend at least partially on
GLI downregulation
To investigate the importance of GLI downregulation for
the antitumor effects of NT1721 we overexpressed myc-
tagged GLI2ΔN [21] in PDAC cells (Additional file 1: Figure
S1a). We compared the effect of NT1721 treatment on the
viability of GLI2ΔN-overexpressing and GFP-expressing
control cells. As shown in Additional file 1: Figure S1b,
treatment with a low concentration of NT1721 (250 nM)
failed to reduce the viability of GLI2ΔN-overexpressing cells
in both cell lines while significantly reducing the viability of
GFP-expressing cells by 20–30%. Treatment with 500 nM
NT1721 did not reduce the viability of NT1721-treated
GLI2Δ2-expressing Capan1 cells while reducing the viability
of the control cells by 50%. The viability of Panc1 cells
treated with 500 nM NT1721 was reduced to a lesser extend
in GLI2Δ2-expressing cells compared to the control cells.
These results suggest that the effects of NT1721 may at least
partially relay on GLI downregulation. To further investigate
this we then determined the effects of NT1721 on GLI1,
BCL2 and ZEB1 mRNA levels in GLI2ΔN-overexpressing
and GFP-expressing control cells: As shown in Additional
file 1: Figure S1c, GLI2ΔN overexpression prevented GLI1
downregulation in both Panc1 and Capan1 cells after treat-
ment with 250 nM NT1721 while the GLI1 mRNA levels
were reduced by > 80% in NT1721-treated, GFP-expressing
control cells. This result was expected given that GLI2 in-
duces GLI1 transcription [23]. NT1721 failed to downregu-
late BCL2, a direct GLI target gene, in GLI2ΔN-expressing
cells while NT1721 reducing BCL2 expression levels by >
70% in control cells (Additional file 1: Figure S1c). We also
assessed ZEB1 expression in these cells since forced GLI2
expression has been shown to increase ZEB1 expression in
pancreatic cancer cells [39]. As shown in Additional file 1:
Figure S1c, ZEB1 was downregulated to a significantly lesser
degree in GLI2ΔN-overexpressing cells compared to GFP-
expressing control cells. Taken together, these results
suggest that the antitumor effects of NT1721 may at least
partially depend on GLI downregulation.
NT1721 reduced tumor growth, metastasis and
significantly prolonged survival in orthotopic mouse
models of pancreatic cancer
To study the in vivo efficacy of NT1721 against pancreatic
cancer we first treated NSG mice bearing orthotopically
growing Panc1 luciferase-expressing (luc+) tumors with 30
mg/kg of NT1721 for 3 consecutive days per week or the
vehicle control (5% DMSO / 30% solutol in PBS) [20]. Bio-
luminescent imaging revealed a statistically significant ~ 4
fold difference between the treatment and the control
groups 18 days after the treatment started (p = 1 × 10− 6)
(Fig. 5a). The mice were euthanized after 5 weeks of treat-
ment and the weight of the primary tumor was determined.
As shown in Fig. 5b, the tumor weight was significantly
lower (by 54%) in treated mice compared to the control
mice (p = 0.0001). To investigate the effect of NT1721 on
liver metastasis we harvested the livers after 5 weeks of
treatment, prepared tissue slides and quantified the number
of tumor foci/μm2 in the liver tissue from NT1721-treated-
and control mice. As shown in Fig. 5c, NT1721 significantly
reduced the number of tumor foci in the liver (by 92%)
compared to control mice (n = 8, p = 0.0007), indicating
that NT1721 efficiently reduced metastasis formation in the
liver. We then compared the antitumor efficacy of NT1721
and gemcitabine by treating tumor-bearing mice with
NT1721 (30mg/kg) or gemcitabine (100mg/kg, twice per
week) (n = 16). As shown in Fig. 5d, we detected a signifi-
cant difference in tumor growth between NT1721- and
gemcitabine-treated mice: Compared with the control mice,
tumor growth was reduced by 61% in the NT1721-treated
mice and by 44% in the gemcitabine-treated group
(p = 0.0002), suggesting that NT1721 may inhibit tumor
growth better than gemcitabine. To assess the influence of
NT1721 and gemcitabine on metastasis we treated mice
bearing luc+-tumors for 5 weeks, injected D-luciferin, eu-
thanized them and immediately compared the biolumines-
cent signals from the livers in the control and treatment
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groups (n = 4). Livers from the NT1721-treated group dis-
played 8-fold lower bioluminescent signals than the control
group; in contrast, livers from the gemcitabine-treated mice
showed only a 5-fold reduction in bioluminescent signals
compared to the control (Fig. 5e). The difference between
the control and the NT1721 group was statistically signifi-
cant (p = 0.00286). However, the difference between the
NT1721- and gemcitabine-treated groups did not reach
statistical significance (p = 0.0571).
We then compared the efficacy of NT1721 and gemci-
tabine in a second mouse model: NSG mice bearing
orthotopically growing Capan1 luc+ tumors were treated
with NT1721, gemcitabine or the vehicle control. Bio-
luminescent imaging showed that both NT1721 and
gemcitabine reduced the tumor growth in treated mice
compared to the control group in a comparable manner
during the first 25 days of treatment (Fig. 6a). However,
weighing the primary tumors after 5 weeks of treatment
revealed that mice treated with NT1721 had smaller tu-
mors compared to mice treated with gemcitabine.
NT1721-treated mice showed an 82% reduction in
tumor growth while gemcitabine decreased the tumor
growth only by 66% compared to the control group. The
difference in tumor weight between the NT1721- and
the gemcitabine-treated group was statistically signifi-
cant (p = 0.045) (Fig. 6b,c). To compare the influence of
NT1721 and gemcitabine on tumor growth and survival
times of mice bearing more advanced tumors Capan1
Fig. 5 NT1721 inhibited tumor growth and reduced liver metastases in an orthotopic model of pancreatic cancer. Male NSG mice bearing
orthotopically growing Panc1 luc+ tumors were treated 12 days after tumor injection with 30 mg/kg NT1721 (three times per week), gemcitabine
(100 mg/kg, twice per week) or with the vehicle control. a Bioluminescent signals. The mice were imaged on the indicated days (n = 9). *
indicates a significant difference between groups on day 18 (p = 1 × 10− 6). Representative pictures of mice from both groups are shown on the
right. b Tumor weight after 5 weeks of treatment with NT1721. c Tumor foci in the liver (n = 8). Tissue slides of livers from mice treated with
either NT1721 or gemcitabine for 5 weeks were prepared and the number of tumor foci was quantified as described in the Material and methods
section. Representative pictures of whole livers from control and NT1721-treated mice are shown below the graphs. d Comparison of the in vivo
efficacy of NT1721 and gemcitabine. The graph shows the percentage of tumor growth in NT1721- and gemcitabine-treated mice compared to
the average in control mice (data from 2 independent experiments). e Decreased metastasis formation in liver. The mice (n = 4 per group) were
injected with D-luciferin after 5 weeks of treatment with NT1721 or gemcitabine and then euthanized. The livers were immediately harvested and
used for bioluminescent imaging. The Mann-Whitney test was used to determine the p values indicated above the graphs
Kowolik et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:431 Page 10 of 15
luc+ tumors were allowed to grow orthotopically for 25
days (instead of only 12 days) before the treatment
started: NT1721 clearly decreased the tumor growth of
the more advanced tumors while gemcitabine did not
cause an obvious decrease in tumor growth (Fig. 6c). As
shown in Fig. 6d, treatment with NT1721 statistically
significantly prolonged the median survival time to 71
days compared to gemcitabine-treated mice (44 days,
p = 0.0007) and the control group (39 days, p = 0.0007).
Taken together, these results show that NT1721 might
be more efficacious against advanced tumors than
gemcitabine.
NT1721 attenuated HH/GLI signaling in vivo
To assess the effect of NT1721 on GLI signaling in vivo
we used tumor tissue from individual mice bearing
Capan1 tumors for Western blot and qPCR analysis of
GLI2 and GLI target genes. As shown in Fig. 7a,b,
treatment with NT1721 reduced the protein expression of
GLI2, PTCH1 and BMI1, statistically significantly by 72,
83 and 78%, respectively, recapitulating the decreases seen
in PDAC cell lines in vitro. We also compared the effect
of gemcitabine and NT1721 on the mRNA expression of
DNMT1, a direct target gene of GLI1 [13]. DNMT1 ex-
pression was significantly reduced in NT1721-treated
mice, while gemcitabine-treated mice showed DNMT1
upregulation (Fig. 7c). Taken together, our data suggest
that NT1721 attenuated GLI signaling in vivo.
NT1721 also significantly reduced the mRNA expres-
sion of two genes involved in cell cycle progression,
CCNE1 and CDK2, by 64 and 45%, respectively, in
Capan1 tumors (Fig. 7c) and by 50 and 60%, respectively,
in Panc1 tumors (Fig. 7d). The results indicate that
NT1721 might, at least partially, decrease the cell cycle
progression and thus tumor growth through CCNE1 and
CDK2 downregulation. In contrast, CCNE1 and CDK2
Fig. 6 NT1721 displays better antitumor efficacy than gemcitabine and prolongs survival of mice with advanced pancreatic cancer. Male NSG
mice were orthotopically implanted with Capan1 luc+ cells. Treatment started with 30 mg/kg NT1721 (three times per week), gemcitabine (100
mg/kg, twice per week) or the vehicle control (n = 7 per group) 12 days (a, b) or 25 days (d) after cell implantation. a Bioluminescent signals. The
mice were imaged on the indicated days. The asterisk indicates a significant difference between the control group and treatment groups
(NT1721 or gemcitabine) on day 25 (p < 0.05). b Tumor weight after 5 weeks of treatment with NT1721 or gemcitabine. P values were
determined using Mann-Whitney test and are indicated in the graphs. c Photos of the representative primary tumors from mice that were treated
with NT1721 or gemcitabine and euthanized after 5 weeks of treatment. d Survival curves. Treatment with NT1721 or gemcitabine started on day
25 after tumor implantation (n = 6). The log-rank test was used to determine p values: The difference in survival between the control and
gemcitabine treated group was significant (p = 0.029); the difference between the gemcitabine-treated and the NT1721-treated group was also
significant (p = 0.0007)
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mRNA expression in gemcitabine-treated mice was sig-
nificantly upregulated in both Capan1 and Panc1 tumors
compared to the control group. Since upregulated ex-
pression of CDK2, CCNE, DNMT1 is associated with ac-
celerated cell cycle progression and thus tumor growth
[33, 40] these results suggest that the tumors might have
started to develop a drug resistance after initially
responding to the treatment with gemcitabine (Fig. 6a,c).
Discussion
PDAC is still one of the deadliest cancers since 80% of
patients have unresectable, metastatic disease at the time
of diagnosis and more than 80% of patients undergoing
surgery relapse [4]. New treatment options are desper-
ately needed since the outcome for PDAC patients has
not significantly improved over the past three decades.
Here we investigated the anti-PDAC activity of a
new ETP, NT1721. The biological activity of ETPs
has been linked to various molecular mechanisms
[41–43]. We show for the first time that an ETP,
NT1721, can attenuate HH signaling through down-
regulation of the main mediators of HH signaling,
GLI1 and GLI2. Treatment of PDAC cells with
NT1721 decreased the expression of GLI target genes
associated with EMT/ metastasis, drug resistance and
the self-renewal of CSCs. These results are in line
with several reports showing that HH inhibition can
reduce CSC growth, chemoresistance and EMT in
PDAC [17, 18, 35, 44, 45]. It is noteworthy that sev-
eral of the genes (GLI1, BMI1, DNMT1, ZEB1, ZEB2)
that were downregulated by NT1721 have prognostic
value in PDAC since high expression levels of these
genes are associated with shorter survival in PDAC
patients [40, 46–48]. Reducing GLI expression has
also the potential to decrease treatment failure due to
an acquired drug resistance: Several studies have
demonstrated that treatment with gemcitabine in-
duced GLI expression, which led to GLI-mediated
upregulation of stem cell genes such as CD24,
ABCG2, BMI1 and gemcitabine resistance [7, 44, 49].
Fig. 7 NT1721-mediated changes in gene expression in vivo. a Tumors from individual mice bearing Capan1 tumors were harvested and used for
Western blots analysis (n = 4 per group). b Band intensities from (a) were quantified with ImageJ software and normalized to β-actin expression.
The graphs represent the ratio of mean value of treated mice to control mice ± SD. p values for the comparison of treated and control mice are
indicated above the graphs. c and d Tumors from mice bearing Capan1 tumors (c) or Panc1 tumors (d) were harvested after 5 weeks of
treatment with NT1721 or gemcitabine and used for qPCR analysis (n = 4 per group). The data were normalized to ACTB. The graphs show the
fold difference ± SD in mRNA expression in NT1721- or gemcitabine-treated mice compared to control mice. P values for the comparison of
treated and control mice are indicated above the graphs
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Resistance to a BRAF inhibitor, vemurafenib, has also
been linked to GLI overexpression [36]. Moreover,
PDAC cells displaying an acquired resistance to the
BET bromodomain inhibitor JQ1 showed dramatically
elevated GLI2 levels [50]. Treatment of these resistant
cells with HH inhibitors or GLI knockdown restored
their drug sensitivity [7, 36, 44, 49, 50]. Taken to-
gether these studies indicate that inhibiting the HH
pathway could improve the prognosis for PDAC pa-
tients by potentially preventing treatment failure due
to inherent or acquired upregulation of tumor stem
cell and/or drug resistance genes.
HH inhibitors such as cyclopamine (SMO inhibitor)
or GANT61 (GLI inhibitor) have shown promising re-
sults in vitro and in vivo against PDAC: Cyclopamine
decreased the viability of several PDAC cell lines, re-
duced invasion and reversed gemcitabine resistance
[17, 18, 51]. However, cyclopamine, like other SMO-
targeting hedgehog inhibitors (erismodegib, vismode-
gib), had no effect on HH ligand-independent cell
lines such as Panc1 at low micromolar concentrations
(< 10 μM) ([17, 51], Fig. 3). A report by Yauch et al.
shows that the sensitity of PDAC cell lines to SMO-
based HH inhibitors does not correlate with GLI1 or
SMO mRNA expression levels at low drug concentra-
tions; the authors concluded that the decrease in cell
viability at high concentrations of SMO inhibitors may
be due to off-target effects [52]. However, GANT61,
which directly targets GLI downstream of SMO, inhib-
ited the growth of HH ligand-independent Panc1 cells
with an reported IC50 value of 5 μM after 48 h treat-
ment [53]. Thus, GLI inhibitors like GANT61 are ad-
vantageous in cancers where SMO contains an
activating mutation or GLI activation is SHH ligand-
independent and driven by e.g. KRAS mutations or by
TGFβ-driven GLI2 expression [12]. Since NT1721 po-
tently (IC50 < 1 μM) inhibited the growth of HH
ligand-independent Panc1 cells it is unlikely that
NT1721 targets SMO or the HH pathway upstream of
SMO. Given that GLI2 can directly induce GLI1 tran-
scription and given that NT1721 downregulated GLI2
mRNA expression at an earlier time point and to a
greater degree than GLI1 mRNA expression it seems
possible that NT1721 interfered with TGFβ-induced
GLI2 mRNA expression. However, the exact mechan-
ism how NT1721 mediates GLI downregulation needs
to be further investigated.
Conclusion
In summary, NT1721 displayed better efficacy in con-
trolling tumor growth and metastasis in preclinical
orthotopic mouse models of PDAC than the standard-
of-care drug, gemcitabine. Importantly, NT1721 is or-
ally available, well tolerated in mice and significantly
prolonged survival compared to the standard-of-care
drug, gemcitabine. Thus, our data provide a rational
for testing NT1721 in the clinic either as a single
agent or potentially in combination with gemcitabine
or other therapeutic agents in PDAC patients overex-
pressing GLI transcription factors.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13046-019-1445-z.
Additional file 1: Figure S1. Antitumor effects of NT1721 depend at
least partially on GLI downregulation. a Overexpression of myc-tagged,
activated GLI2 (GLI2Δ2) in Panc1 and Capan1 cells. b Viability of GLI2ΔN-
overexpressing and GFP-expressing control cells after treatment with 250
nM NT1721. The symbols (1* - 3*) indicate statistically significant differ-
ences compared to the control with p values of 0.003, 0.01 and < 0.001,
respectively. c Expression levels of GLI1, BCL2 and ZEB1 in GLI2ΔN-
overexpressing and GFP-expressing control cells after treatment with 250
nM NT1721. The graphs represent the mean ± SD from triplicate values.
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